Zenotech Laboratories

Zenotech Laboratories EBIT per Share

The EBIT per Share of Zenotech Laboratories (532039.BO) as of Nov 22, 2026 is -0.31 INR. In the previous year, EBIT per Share was 1.50 INR — a change of -120.75% (lower).

EBIT per Share

-0.31INR

YoY

-120.75%

Last updated:

EBIT per Share of Zenotech Laboratories is 2026 -0.31 INR. EBIT per Share of Zenotech Laboratories was 2025 1.50 INR. It decreases by -120.75% lower compared to the previous year.

The Zenotech Laboratories EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2019
-1.22 INR
Jan 1, 2020
1.72 INR
Jan 1, 2021
-0.01 INR
Jan 1, 2022
1.81 INR
Jan 1, 2023
2.39 INR
Jan 1, 2024
1.67 INR
Jan 1, 2025
1.50 INR
Jan 1, 2026
-0.31 INR
The Zenotech Laboratories EBIT per Share history
YEAREBIT per ShareYoY
-0.31INR-120.75%
1.50INR-10.19%
1.67INR-30.34%
2.39INR+32.64%
1.81INR-14,597.24%
-0.01INR-100.72%
1.72INR-240.72%
-1.22INR-36.33%
-1.92INR-5.55%
-2.03INR-36.41%
-3.20INR+44.43%
-2.21INR-39.85%
-3.68INR-44.03%
-6.58INR+140.87%
-2.73INR-71.71%
-9.65INR+176.70%
-3.49INR-36.95%
-5.53INR+38.94%
-3.98INR-1,405.04%
0.31INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zenotech Laboratories Stock analysis

What does Zenotech Laboratories do? Zenotech Laboratories Ltd manufactures and markets pharmaceutical products, specializing in oncology, biotechnology, and general injectables. The company operates from a manufacturing facility in Turkapally village, Shamirpet Mandal, Telangana, producing specialty generic injectables for the pharmaceutical sector. Its products are sold to healthcare providers and distributors within the pharmaceutical industry, targeting markets that require specialized injectable solutions. The firm's business model focuses on the production and distribution of generic injectables, leveraging its facility in Telangana to serve both domestic and international markets. By concentrating on oncology and biotechnology injectables, Zenotech addresses specific medical needs, generating revenue through the sale of these high-demand pharmaceutical products to hospitals, clinics, and pharmaceutical distributors. Zenotech Laboratories Ltd's revenue streams come from the sale of its specialty generic injectables, including oncology and biotechnology products, to healthcare institutions and distribution networks. The company's manufacturing capabilities in Telangana support its role as a supplier in the pharmaceutical supply chain, with a focus on injectable formulations that cater to critical healthcare applications. Zenotech Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zenotech Laboratories stock

EBIT per Share of Zenotech Laboratories is -0.31 INR in 2026.

EBIT per Share of Zenotech Laboratories changed from 1.50 INR to -0.31 INR, representing a -120.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Zenotech Laboratories since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Zenotech Laboratories

All Key Metrics — Zenotech Laboratories